Therapeutic potential of proapoptotic molecule Noxa in the selective elimination of tumor cells

Cancer Science

Volumn 100, Issue 4, 2009, Pages 759-769

  Suzuki, Saori ^a   Nakasato, Makoto ^a   Shibue, Tsukasa ^a,b   Koshima, Isao ^a   Taniguchi, Tadatsugu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; POLYMER; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; GLUTATHIONE TRANSFERASE; PMAIP1 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; DRUG SCREENING; FEMALE; GENE THERAPY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NICK END LABELING; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GENE THERAPY; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449099150     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01096.x     Document Type: Article

References (39)

1. Lucas R, Keisari Y. Innovative cancer treatments that augment radiotherapy or chemo-therapy by the use of immunotherapy or gene therapy. Recent Patents Anticancer Drug Discov 2006; 1: 201-8.
2. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253: 49-53.
3. Martin CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-34.
4. Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007; 28: 13-20.
5. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
6. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-49.
7. Shibue T, Taniguchi T. BH3-only proteins. Integrated control of apoptosis. Int J Cancer 2006; 119: 2036-43.
8. Adams JM. Ways of dying: Multiple pathways to apoptosis. Genes Dev 2003; 17: 2481-95.
9. Daniel NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-19.
10. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Diff 2006; 13: 1325-38.
11. Fujiwara T, Tanaka N, Kanazawa S et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small cell-lung cancer. J Clin Oncol 2006; 24: 1689-99.
12. Seth P, Katayose D, Li Z et al. A recombinant adenovirus expression wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther 1997; 4: 383-90.
13. Shaw P, Bovey R, Tardy S et al. Induction of apoptosis by wild-type p53 in human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-9.
14. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003; 9: 5055-67.
15. Clayman GL, El-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-32.
16. Blagoskolonny MV, El-Deiry WS. Acute overexpression of WT p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 1998; 75: 933-40.
17. Yoo GH, Piechocki MP, Oliver J et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004; 114: 1871-9.
18. Ganjavi H, Gee M, Narendran A et al. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: Sensitization of cisplatin and doxorubicin. Cancer Gene Ther 2005; 12: 397-406.
19. Cristofanilli M, Krishnamurthy S, Guerra L et al. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: Safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 2006; 107: 935-44.
20. Gomez-Manzano C, Fueyo J, Kyritsis AP et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997; 89: 1036-44.
21. Ito H, Kanazawa T, Miyoshi T et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of the p53 status. Hum Gene Ther 2005; 16: 685-98.
22. Oda E, Ohki R, Murasawa H et al. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-8.
23. Shibue T, Takeda K, Oda E et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003; 17: 2233-8.
24. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-94.
25. Yu J, Zhang L, Hwang PM et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-82.
26. Shibue T, Suzuki S, Okamoto H et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J 2006; 25: 4952-62.
27. Mansilla S, Bataller M, Portugal J. Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med Chem 2006; 6: 589-602.
28. Nagahara H et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27 Kip1 induces cell migration. Nat Med 1998; 4: 1449-52.
29. Soule HD et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50: 6075-86.
30. Tait L et al. Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50: 6087-94.
31. Ohtani S, Kagawa S, Tango Y et al. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional administration of adenoviral p53 in.vivo. Mol Cancer Ther 2004; 3: 93-100.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
33. Mizuguchi H, Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004; 15: 1034-44.
34. Raper ES, Chirmule F, Lee FS et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
35. Fukushima S, Miyata K, Nishiyama N et al. PEGylated polyplex micelles from triblock catiomers with spatially ordered layering of condensed pDNA and buffering units for enhanced intracellular gene delivery. J Am Chem Soc 2005; 127: 2810-11.
36. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmaco Ther 2006; 112: 630-48.
37. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
38. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193-210.
39. Chu D, Lu J. Novel therapies in breast cancer: What is new from ASCO 2008. J Hematol Oncol 2008; 1: 16-28.